CA Patent

CA2845553C — Tenofovir alafenamide hemifumarate

Assigned to Gilead Sciences Inc · Expires 2019-05-28 · 7y expired

What this patent protects

A hemifumaiate form of 9-[(R>2-[[(S)-[[(S>1- (isopropoxycaibonyl)etJhyl]amino]phenoxyphosphinyl]m (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifurnarate (e.g., anti-HTV and anti-HBV therapies). Formula (I).

USPTO Abstract

A hemifumaiate form of 9-[(R>2-[[(S)-[[(S>1- (isopropoxycaibonyl)etJhyl]amino]phenoxyphosphinyl]m (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifurnarate (e.g., anti-HTV and anti-HBV therapies). Formula (I).

Drugs covered by this patent

Patent Metadata

Patent number
CA2845553C
Jurisdiction
CA
Classification
—
Expires
2019-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.